P-76 Prevalence of Tuberculosis-Destroyed Lung and Status of Medication Usage in Patients with Tuberculosis-Destroyed Lung

Objective: To define prevalence of tuberculosis-destroyed lung (TDL) in Korea and prescribing status of respiratory medication in TDL patients. Method: We reviewed patients with TDL (ICD-10 code: B90, J984) as primary to fifth diagnosis between January 2011 and December 2015, using Korea Health Insurance Review and Assessment Service(HIRA) database. Result: A total of 645,031 patients from HIRA database were enrolled. Mean age was 59.54 ± 11.91 (mean ± standard error); age under 40, in the 40s, 50s, 60s, 70s and 80 or older were respectively 3.4% (21,657), 19.1% (123,293), 28.6% (184,343), 26.3% (169,531), 17.9% (115,683), and 4.7% (30,524); 44.2% (284,886) were male; 50.2% (323,854) were using systemic bronchodilator. Use of theophylline, inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long-acting muscarinic antagonist (LAMA), ICS/LABA, LABA/LAMA, short-acting beta-2 agonist (SABA), short-acting muscarinic antagonist (SAMA), SABA/SAMA, leukotriene receptor antagonist (LTRA), phosphodiesterase-4 inhibitor (PDE4i) and any of respiratory medication were respectively 35.6% (229,461), 1.4% (9,063), 7.5% (48,514), 11.7% (75,317), 0.4% (2,830), 20.1% (129,603), 11.6% (74,565), 0.1% (564), 31.3% (201,905), 0.4% (2,586) and 71.3% (460,212). Conclusion: TDL is highly prevalence disease in Korea, and approximately half of the patients with TDL using at least one type of bronchodilator and large proportion of them were form in the inhaler were noted.